Skip to main content
Clinical Trials/NCT02443727
NCT02443727
Completed
Early Phase 1

The Role of Oxytocin in the Perception of Infant Faces

Rodrigo Cardenas0 sites71 target enrollmentApril 2015

Overview

Phase
Early Phase 1
Intervention
Syntocinon (synthetic oxytocin)
Conditions
Healthy
Sponsor
Rodrigo Cardenas
Enrollment
71
Primary Endpoint
Functional Magnetic Resonance Imaging (fMRI) Data
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The main objective of this project is to study whether intranasal oxytocin (OT) affects how young adults perceive and attend to infant and adult faces. Based on existing research the investigators predict that oxytocin will facilitate the allocation of attentional resources on infant faces (compared to adult faces). The investigators also predict that oxytocin will enhance the activity of reward neural-networks associated with the perception of infant faces. The behavioral effects of OT (visual attention and face recognition) will be measured with eye-tracking while participants look at photographs of adult and infant faces. Neurological effects (the activity of emotion and reward networks) will be measured with functional Magnetic Resonance Imaging (fMRI) while participants look at infant faces on a computer screen.

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
September 2016
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Sponsor
Rodrigo Cardenas
Responsible Party
Sponsor Investigator
Principal Investigator

Rodrigo Cardenas

Lecturer

Penn State University

Eligibility Criteria

Inclusion Criteria

  • Healthy Volunteers
  • Norma or corrected to norma vision
  • Participants are non parents
  • Able to provide written informed consent and to comply with all study procedures

Exclusion Criteria

  • Dementia or severe cognitive disorders
  • Endocrine disease or malignancy
  • Nasal obstruction or upper-respiratory tract infection
  • Current or previous psychiatric disorder
  • Current or previous use of psychoactive drugs
  • Alcoholism or substance abuse
  • History of seizures
  • Neurological Disorder
  • Previous head trauma
  • Hypertension

Arms & Interventions

Intranasal oxytocin group

Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).

Intervention: Syntocinon (synthetic oxytocin)

Placebo group

The placebo is identical to the oxytocin formulation with the exception of the active compound. Participants will self-administer three puffs per nostril of placebo (6 puffs total).

Intervention: Placebo

Outcomes

Primary Outcomes

Functional Magnetic Resonance Imaging (fMRI) Data

Time Frame: 45 minutes after OT manipulation

The effect of OT will be assessed by determining changes in brain activation between treatment and placebo groups.

Eye movements data

Time Frame: 45 minutes after OT manipulation

The effect of OT will be assessed by determining changes in eye movements between treatment and placebo groups.

Secondary Outcomes

  • Implicit Attitudes toward infants(45 minutes after OT manipulation)
  • Theory of mind(45 minutes after OT manipulation)

Similar Trials